In India, the wedding season has sparked a surge in the use of GLP-1 receptor agonists, such as Mounjaro and Wegovy, marketed as quick weight loss solutions for brides-to-be. These medications, originally designed for chronic obesity and type 2 diabetes, are increasingly being sought by women under societal pressure to conform to aesthetic standards. Aditi, a 26-year-old finance worker from Mumbai, shared her experience of losing 10 kg with Mounjaro before her wedding. However, medical professionals like Dr. Rajat Goel, a bariatric surgeon, report that over 20 percent of inquiries for obesity injections now come from brides, raising concerns about the drugs being used without proper medical oversight. Experts warn that while these drugs can lead to significant weight loss, they are not cosmetic solutions and can cause serious side effects, including nausea and pancreatitis. Furthermore, many brides stop using the injections after their weddings, leading to rapid weight regain. As the Indian weight loss market is projected to reach ₹80 billion ($851.79 million) by 2030, the medical community stresses the importance of sustainable weight management over short-term cosmetic goals.